


This article was downloaded by: [Tallinn University of Technology]

On: 4 January 2010

Access details: Access Details: [subscription number 907226556]

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Synthetic Communications

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597304>

Synthesis of 5,5'-Disubstituted Bimorpholines

Kristin Lippur ^a; Cindy Elmers ^a; Tiit Kailas ^a; Aleksander-Mati Müürisepp ^a; Tõnis Pehk ^b; Tõnis Kanger ^a; Margus Lopp ^a

^a Department of Chemistry, Faculty of Science, Tallinn University of Technology, Tallinn, Estonia ^b National Institute of Chemical Physics and Biophysics, Tallinn, Estonia

Online publication date: 29 December 2009

To cite this Article Lippur, Kristin, Elmers, Cindy, Kailas, Tiit, Müürisepp, Aleksander-Mati, Pehk, Tõnis, Kanger, Tõnis and Lopp, Margus(2010) 'Synthesis of 5,5'-Disubstituted Bimorpholines', Synthetic Communications, 40: 2, 266 — 281

To link to this Article: DOI: 10.1080/00397910902964874

URL: <http://dx.doi.org/10.1080/00397910902964874>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHESIS OF 5,5'-DISUBSTITUTED BIMORPHOLINES

Kristin Lippur,¹ Cindy Elmers,¹ Tiiu Kailas,¹
Aleksander-Mati Müürisepp,¹ Tõnis Pehk,²
Tõnis Kanger,¹ and Margus Lopp¹

¹Department of Chemistry, Faculty of Science, Tallinn University of
Technology, Tallinn, Estonia

²National Institute of Chemical Physics and Biophysics, Tallinn, Estonia

A general method for the synthesis of 5,5'-disubstituted bimorpholines is proposed. According to the method, methyl-substituted and benzyl-substituted compounds were synthesized, starting from tartaric ester acetal. Target compounds were obtained in good yield and high enantiomeric purity.

Keywords: Asymmetric synthesis; bimorpholine; cyclic diamines

INTRODUCTION

Enantiomerically pure nitrogen-containing heterocycles are of great importance in organic chemistry. Their use as chiral auxiliaries, chiral reagents, and chiral ligands in many organic reactions is well known.^[1] Additionally, such heterocycles are important building blocks for bioactive compounds.^[2] Many pharmaceutical agents contain morpholine derivatives as part of their structure. The C-substituted morpholines have revealed antidepressant, appetite suppressant, antioxidative, and antitumor biological activity.^[3]

At the same time, the expanding scope of asymmetric aminocatalysis^[4] has led to the synthesis and wide use of a variety of diamines. These compounds are efficient organocatalysts in many C–C– and C-heteroatom bond-forming reactions.^[5] C₂-symmetric bridged compounds that have a C–C bond between two heterocyclic rings and possess both H donor and acceptor sites and a secondary amino group are potential bifunctional catalysts (bimorpholines **1** and **2**, Fig. 1). Substitution in the morpholine rings makes them also attractive synthetic building blocks for bioactive molecules.

In connection with our ongoing project of organocatalysis with diamines, we have previously reported on the synthesis of (2*S*,2'*S*)-bimorpholine **1** and (3*R*,3'*R*)-bimorpholine **2**.^[6] Derivatives of these bimorpholines have been used as organocatalysts in several reactions.^[7] The main idea of their preparation is to

Received March 5, 2009.

Address correspondence to Tõnis Kanger, Department of Chemistry, Faculty of Science, Tallinn University of Technology, Akadeemia tee 15, 12618 Tallinn, Estonia. E-mail: kanger@chemnet.ee




Figure 1. 2,2'-Bimorpholine **1** and 3,3'-bimorpholine **2**.

introduce the chiral structure of a readily available and cheap tartaric acid ester to a backbone of a cyclic derivative. The key steps of the synthesis are the introduction of nitrogen-containing functionality into tartaric acid derivatives and the intramolecular cyclization.

Recently, we have reported on the synthesis of unsubstituted bimorpholine **1** via amidation of tartaric ester with 2-aminoethanol, followed by cyclization.^[8] This significant improvement of the preparation scheme increased the yield of the target compound after the six-step sequence to 35%.

In the present work, we describe the synthesis of new 5,5'-disubstituted bimorpholines as a general objective to functionalize the α -position of the nitrogen atom in bimorpholines. The proposed scheme allows introduction of various substituents and is based on the abovementioned route through amide formation. Thus, it is an efficient synthesis of enantiomerically pure 5,5'-dimethyl-2,2'-bimorpholines **3** and **4** together with 5,5'-dibenzyl derivative **5** (Fig. 2).

RESULTS AND DISCUSSION

Stereogenic centers in target compounds at bridgehead carbons were transformed from tartaric ester and methyl or benzyl-substituted carbons from (*S*)-aminoalcohol **7**. Derivatives **3** and **5** were obtained from (*R,R*)-tartaric ester acetal **6**, whereas its diastereoisomeric **4** was obtained from (*S,S*)-tartaric ester acetal.

The synthesis started with the cyanide-catalyzed amidation^[9] of tartaric ester acetal **6** with aminoalcohols **7** (**a** or **b**), which afforded amides **8** (**a** or **b**, respectively) in more than 80% yield (Scheme 1). In a single step, the skeleton of the target






Figure 2. 5,5'-Disubstituted bimorpholines.

Scheme 1. Synthesis of bimorpholine **5**.

bimorpholine was formed. Reduction of amides with LiAlH_4 gave rise to amines **9a**, **b** in good yield. The synthesis of bimorpholines **3** and **5** was completed analogously to our previous preparation of unsubstituted bimorpholines (described by us before).^[8] Thus, secondary amino groups of compounds **9a**, **b** were protected with benzyl bromide in the presence of diisopropylethyl amine (DIPEA) in 80–98% yield.

When K_2CO_3 was used instead of DIPEA, the reaction was not complete in 2 days, and a mixture of starting material and monobenzylated and dibenzylated products was detected. The acetal groups in compounds **10a**, **b** were removed under acidic conditions, which gave the desired tetraols **11a**, **b** for the cyclization. So far, all reactions were high-yielding. The final step of the sequence was intramolecular cyclization. Tetraols **11a**, **b** were cyclized in a one-step procedure with NaH and 1-(*p*-toluenesulfonyl)imidazole,^[10] affording bimorpholines **12**. Benzyl derivative **12b** was obtained with a moderate yield (63%) and deprotection of it by ammonium formate afforded the desired bimorpholine **5** in 90% yield.

Methyl substituted bimorpholine **12a** was obtained via cyclization in an unexpectedly poor yield—only 18%. A similar phenomenon was observed in the synthesis of *trans*-2,5-disubstituted morpholines by Lanman and Myers^[10]—*N*-benzyl-protected α -methyl substituted synthon gave a mixture of products in the cyclization. The intermediate aziridinium ion was reversibly formed in the course of the reaction. Nonregioselective opening of it led to several products, lowering the yield of the target compound. Lanman and Myers showed that the use of *p*-toluenesulfonamide protective group is critical to increase the yield of the target compound. Therefore, we used the tosyl group instead of the benzyl group to protect amine **9a** (Scheme 2). The choice of the base played a crucial role in the



Scheme 2. Synthesis of bimorpholine 3.

reaction. The selective *N*-protection in the presence of primary hydroxyl groups was achieved by using MgO as the base^[11] (Table 1). Although the selective *N*-protection in the presence of Et₃N is described in the literature,^[12] in our case the reaction with compound **9a** resulted in a mixture of undetermined products (entry 1). The use of sterically more hindered base (DIPEA) resulted in 24% yield (entry 2). When NaH was added to the reaction, only the starting material was recovered (entry 3). The best results were obtained by using MgO in THF/H₂O (entries 4–6)—40% of the yield was achieved within 24 h. Increasing the reaction time to 5 days increased the isolated yield of the product to 52%. When the reaction was performed in the microwave reactor during 1 h at 40–60 °C, it resulted in 22% yield together with a considerable amount of by-products (entry 7). When dimethylformamide (DMF) was used as the solvent in the microwave-assisted reaction, no reaction occurred (entry 8).

The synthesis with *N*-tosylated intermediate was similar to the method used in the previous route. Thus, acetal **13a** was deprotected under acidic conditions in 97% yield. Using the present approach, the cyclization of tetraol **14a** was efficient and afforded bimorpholine **15a** in 71% yield. It is likely that the formation of aziridinium intermediate in the present case is retarded because of sulfoxonium ion character of

Table 1. Tosylation of amine **9a**

Entry	Base	Solvent	Temp. (°C)	Reaction time	13a yield (%)
1	Et ₃ N	CH ₂ Cl ₂	RT	48 h	n.d. ^a
2	DIPEA	CH ₂ Cl ₂	0	19 h	24
3	NaH	DMF	0	5 h	n.r. ^b
4	MgO	THF/H ₂ O	RT	24 h	40
5	MgO	THF/H ₂ O	RT	3 d	48
6	MgO	THF/H ₂ O	RT	5 d	52
7	MgO	THF/H ₂ O	MW ^c 40–60	1 h	22
8	MgO	DMF	MW 100	30 min	n.r.

^aNot determined.^bNo reaction.^cMicrowave reactor CEM Discover-S.

tosylamide. The target compound **3** was obtained by the reduction of tosyl amide **15** by LiAlH_4 in 70% yield (Scheme 2).

The diastereoisomer **4** of bimorpholine **3** was synthesized according to the same synthetic route as depicted in Scheme 2, starting from (*S,S*)-tartaric acid ester acetal (see the experimental section for details). All the corresponding intermediates are marked with the letter **c**. We have previously shown that this synthetic route led to unsubstituted bimorpholines with high enantiomeric purity (ee 99%).^[8] Now, the NMR analysis of diastereomeric bimorpholines **3** and **4** revealed that no epimerization takes place in the course of the reactions. Diastereomeric purities of the synthesized compounds were high (>98%), and the same can be concluded for enantiomeric purity.

CONCLUSIONS

In summary, we have developed a general strategy for the synthesis of 5,5'-disubstituted bimorpholines. The substituents and the absolute configuration of those positions are determined by the configuration and structure of the chosen amino alcohol. Bimorpholines **3**, **4**, and **5** were all synthesized in good yield and high enantiomeric purity over six steps. The investigation of catalytic properties of these new compounds is currently under study.

EXPERIMENTAL

General

Chemicals were purchased from Aldrich Chemical Co. and were used as received. Tetrahydrofuran (THF) was distilled over LiAlH_4 . Precoated silica-gel 60 F₂₅₄ plates from Merck were used for thin-layer chromatography (TLC), whereas for column chromatography silica gel KSK40–100 μm was used. Full assignment of ^1H and ^{13}C chemical shifts is based on the 1D and 2D FT NMR spectra measured on a Bruker AMX500, Avance III 400 and Avance III 800 instruments. Solvent peaks (CHCl_3 δ = 7.27, CHD_2OD δ = 3.30, CDCl_3 δ = 77.00, CD_3OD δ = 49.00) were used as chemical shift references. Infrared (IR) spectra were measured on a Perkin-Elmer Spectrum BX Fourier transform (FT)–IR spectrometer. Mass spectra (MS) were recorded on a Shimadzu GCMS-QP2010 spectrometer using EI (70 eV). High-resolution mass spectra (HRMS) were recorded on a Hitachi M80B spectrometer using EI (70 eV) or on LTQ Orbitrap (Thermo Electron). Elemental analyses were performed on a Perkin-Elmer C,H,N,S–Analyzer 2400. Optical rotations were obtained using a Krüss Optronic GmbH Polarimeter P 3002. All reactions sensitive to moisture or oxygen were carried out under Ar atmosphere in oven-dried glassware.

(4*R*,5*R*)-*N,N'*-Bis[(1*S*)-2-hydroxy-1-methylethyl]-2,2-dimethyl-1,3-dioxolane-4,5-dicarboxamide, **8a**

(*S*)-Alaninol **7a** (2.58 mL, 33.16 mmol) and sodium cyanide (81 mg, 1.66 mmol) were added to a solution of (*R,R*)-tartaric acid ester acetal **6** (3.618 g, 16.58 mmol) in MeOH (55 mL). The reaction mixture was refluxed for 48 h. MeOH was evaporated,

and the crude mixture was purified by column chromatography on silica gel (7% MeOH in CH₂Cl₂), affording amide **8a** as a yellow oil (yield 4.029 g, 80%). ¹H NMR (CDCl₃, 500 MHz) δ: 7.16 (br d, *J* = 7.8, 2H, NH), 4.54 (s, 2H, H-4,5), 4.08 (m, 2H, NHCH), 3.67 (dd, *J* = 3.8, 11.2, 2H, CH₂O), 3.51 (dd, *J* = 6.3, 11.2, 2H, CH₂O), 3.39 (br s, 2H, OH), 1.49 (6H, s, 2-CH₃), 1.19 (d, *J* = 6.9, 6H, CH₃). ¹³C NMR (CDCl₃, 125 MHz) δ: 170.05 (CO), 112.51 (C-2), 77.46 (C-4,5), 66.25 (CH₂OH), 47.59 (NHCH), 26.03 (2-CH₃), 16.80 (CH₃CH). IR: ν = 3409, 3088, 2981, 2939, 2880, 1668, 1538, 1456, 1386, 1215, 1090, 1056 cm⁻¹. [α]_D²³ = -27.5 (c 1.45, MeOH). MS *m/z*: 305 (M⁺ + 1), 273, 255, 144, 114. HRMS calcd. for C₁₂H₂₁N₂O₅ (M⁺ - CH₃OH) 273.1449. Found 273.1440.

(4*R*,5*R*)-*N,N'*-Bis[(1*S*)-1-benzyl-2-hydroxyethyl]-2,2-dimethyl-1,3-dioxolane-4,5-dicarboxamide, **8b**

(*S*)-phenylalaninol **7b** (7.287 g, 48.20 mmol) and sodium cyanide (118 mg, 2.41 mmol) were added to a solution of (*R,R*)-tartaric acid ester acetal **6** (5.258 g, 24.10 mmol) in MeOH (80 mL). The reaction mixture was refluxed for 24 h. MeOH was evaporated, and the crude mixture was purified by column chromatography on silica gel (7% MeOH in CH₂Cl₂), affording amide **8b** as a yellow solid (yield 9.777 g, 89%). ¹H NMR (CDCl₃, 400 MHz) δ: 7.36–7.25 (m, 10H, Bn), 7.22 (d, *J* = 8.3, 2H, NH), 4.35 (s, 2H, CHO), 4.32–4.23 (m, 2H, NCH), 3.75 (dd, *J* = 3.7, 11.1, 2H, CH₂OH), 3.64 (dd, *J* = 5.5, 11.1, 2H, CH₂OH), 3.14 (br s, 2H, OH), 2.95 (m, 4H, Bn CH₂), 1.42 (s, 6H, CH₃). ¹³C NMR (CDCl₃, 100 MHz) δ: 170.08 (C=O), 137.40 (*s*-Bn), 129.21 (*o*-Bn), 128.52 (*m*-Bn), 126.64 (*p*-Bn), 112.43 (C(CH₃)₃), 77.26 (CHO), 63.82 (CH₂OH), 52.72 (NCH), 36.96 (Bn CH₂), 25.81 (CH₃). IR: ν = 3408, 3062, 2989, 2937, 1677, 1530, 1454, 1385, 1213, 1091, 1040, 746, 701 cm⁻¹. [α]_D²⁴ = -82.4 (c 1.18, MeOH). MS *m/z*: 456 (M⁺), 365, 347, 134, 120, 91. Anal. calcd. for C₂₅H₃₂N₂O₆ (456.54): C, 65.77; H, 7.07; N, 6.14. Found: C, 65.50; H, 7.04; N, 6.10.

(2*S*,2'*S*)-2,2'-[[(4*S*,5*S*)-2,2-Dimethyl-1,3-dioxolane-4,5-diyl]bis(methyleneimino)]dipropen-1-ol, **9a**

Amide **8a** (2.589 g, 8.51 mol) in THF (60 mL) was added to a suspension of LiAlH₄ (1.937 g, 51.04 mol) in THF (50 mL) at 0°C. After refluxing for 6 h, water (1.9 mL), 15% NaOH solution (1.9 mL), and water (5.7 mL) were added at 0°C. The mixture was filtered and washed with EtOAc. The filtrate was dried over Na₂SO₄. Solvents were evaporated, and the residue was purified by crystallization (petroleum ether/EtOAc), affording amine **9a** as white crystals (yield 2.225 g, 95%, mp 47–49°C). ¹H NMR (CDCl₃, 500 MHz) δ: 3.94 (m, 2H, H-4,5), 3.57 (dd, *J* = 3.7, 10.8, 2H, CH₂O), 3.29 (dd, *J* = 7.0, 10.8, 2H, CH₂O), 2.90 (dm, *J* = 12.3, 2H, NHCH₂), 2.79 (m, 2H, NHCH), 2.75 (dm, *J* = 12.3, 2H, NHCH₂), 2.6 (br s, 4H, NH+OH), 1.39 (6H, s, 2-CH₃), 1.04 (d, *J* = 6.5, 6H, CH₃). ¹³C NMR (CDCl₃, 125 MHz) δ: 108.63 (C-2), 78.81 (C-4,5), 65.71 (CH₂OH), 54.59 (NHCH), 48.62 (CH₂NH), 27.16 (2-CH₃), 16.96 (CH₃CH). IR: ν = 3293, 3119, 2989, 2968, 2934, 2852, 1443, 1379, 1230, 1082, 1056 cm⁻¹. [α]_D²⁴ = +4.9 (c 5.13, MeOH). MS *m/z*: 277 (M⁺ + 1), 245, 187, 130, 88. HRMS calcd. for C₁₂H₂₅N₂O₃ (M⁺ - CH₃OH) 245.1863. Found 245.1869.

(2*S*,2'*S*)-2,2'-[(4*S*,5*S*)-2,2-Dimethyl-1,3-dioxolane-4,5-diyl]-bis(methyleneimino)]bis(3-phenylpropan-1-ol), 9b

Amide **8b** (9.746 g, 21.34 mmol) in THF (60 mL) was added to a suspension of LiAlH₄ (4.861 g, 128.09 mmol) in THF (150 mL) at 0°C. After refluxing for 3 h, water (4.8 mL), 15% NaOH solution (4.8 mL), and water (14.6 mL) were added at 0°C. The mixture was filtered and washed with EtOAc. The filtrate was dried over Na₂SO₄. Solvents were evaporated, and the residue was purified by crystallization (EtOAc/petroleum ether). The mother liquid was purified by column chromatography on silica gel (3% MeOH/NH₃ in CH₂Cl₂), affording amine **9b** as white crystals (yield 8.372 g, 92%, mp 71–77°C). ¹H NMR (CDCl₃, 400 MHz) δ: 7.29–7.14 (m, 10H, Bn), 3.85 (s, 2H, CHO), 3.60 (dd, *J* = 3.6, 11.1, 2H, CH₂OH), 3.34 (dd, *J* = 5.6, 11.1, 2H, CH₂OH), 2.87 (m, 2H, NCH), 2.81–2.75 (m, 4H, NCH₂), 2.74–2.69 (m, 4H, Bn CH₂), 1.29 (s, 6H, CH₃). ¹³C NMR (CDCl₃, 100 MHz) δ: 138.40 (*s*-Bn), 129.16 (*o*-Bn), 128.54 (*m*-Bn), 126.40 (*p*-Bn), 108.49 [C(CH₃)₂], 78.43 (CHO), 62.76 (CH₂OH), 60.68 (NCH), 48.25 (NHCH₂), 37.86 (Bn CH₂), 27.05 (CH₃). IR: ν = 3421, 3290, 3027, 2964, 2860, 1945, 1455, 1380, 1231, 1101, 1065, 743, 700 cm⁻¹. $[\alpha]_D^{23}$ = –31.6 (c 1.18, MeOH). MS *m/z*: 429 (M⁺ + 1), 413, 397, 337, 206, 91. Anal. calcd. for C₂₅H₃₆N₂O₄ (428.58): C, 70.06; H, 8.47; N, 6.54. Found: C, 69.74; H, 8.50; N, 6.50.

(2*S*,2'*S*)-2,2'-[(4*S*,5*S*)-2,2-Dimethyl-1,3-dioxolane-4,5-diyl]-bis[methylene(benzylimino)]dipropen-1-ol, 10a

To a solution of amine **9a** (1.96 g, 7.09 mmol) in CH₃CN (24 mL), DIPEA (3.71 mL, 21.28 mmol) and benzyl bromide (2.53 mL, 21.28 mmol) were added. The reaction mixture was stirred at 40°C for 18 h. CH₃CN was evaporated, water (30 mL) was added, and the mixture was extracted with EtOAc (3 × 20 mL). The organic phase was dried (Na₂SO₄), and solvent was evaporated. The residue was purified by crystallization (petroleum ether/EtOAc), affording benzylated amine **10a** as white crystals (yield 2.595 g, 80%, mp 91–92°C). ¹H NMR (CDCl₃, 500 MHz) δ: 7.30 (m, 4H, *m*-Bn), 7.26 (m, 4H, *o*-Bn), 7.25 (m, 2H, *p*-Bn), 3.85 and 3.39 (2d, *J* = 13.7, 4H, Bn CH₂), 3.59 (m, 2H, H-4,5), 3.33 and 3.30 (2m, 4H, CH₂O), 3.23 (br s, 2H, OH), 3.04 (m, 2H, NCH), 2.59 and 2.51 (dm, 4H, *J* = 14.0, NCH₂), 1.36 (6H, s, 2-CH₃), 0.88 (d, *J* = 6.7, 6H, CH₃). ¹³C NMR (CDCl₃, 125 MHz) δ: 139.29 (*s*-Bn), 128.92 (*o*-Bn), 128.41 (*m*-Bn), 127.11 (*p*-Bn), 109.10 (C-2), 80.41 (C-4,5), 63.18 (CH₂OH), 56.28 (NCH), 54.32 (Bn), 51.41 (CH₂N), 27.25 (2-CH₃), 9.11 (CH₃CH). IR: ν = 3463, 3028, 2964, 2935, 2877, 1946, 1495, 1374, 1223, 1105, 1061, 736, 698 cm⁻¹. $[\alpha]_D^{23}$ = +42.9 (c 1.18, MeOH). MS *m/z*: 456 (M⁺), 425, 232, 220, 178, 148, 91. Anal. calcd. for C₂₇H₄₀N₂O₄ (456.63): C, 71.02; H, 8.83; N, 6.13. Found: C, 70.92; H, 8.87; N, 6.11.

(2*S*,2'*S*)-2,2'-[(4*S*,5*S*)-2,2-Dimethyl-1,3-dioxolane-4,5-diyl]-bis[methylene(benzylimino)]bis(3-phenylpropan-1-ol), 10b

To a solution of amine **9b** (1.000 g, 2.33 mmol) in MeOH (8 mL), DIPEA (1.22 mL, 7.00 mmol) and benzyl bromide (0.83 mL, 7.00 mmol) were added. The

reaction mixture was stirred at 40°C for 16 h. MeOH was evaporated, water (30 mL) was added, and the mixture was extracted with CH₂Cl₂ (2 × 25 mL). The organic phase was dried (Na₂SO₄), and solvent was evaporated. The residue was purified by column chromatography on silica gel (33% EtOAc in petroleum ether), affording benzylated amine **10b** as a white solid (yield 1.392 g, 98%, mp 101–103°C). ¹H NMR (CDCl₃, 400 MHz) δ: 7.43–7.16 (m, 20H, Ar), 4.04 (d, *J* = 13.6, 2H, N-Bn CH₂), 3.70–3.61 (m, 2H, CHO), 3.52 (d, *J* = 13.6, 2H, N-Bn CH₂), 3.40 (d, *J* = 7.4, 4H, CH₂OH), 3.28 (m, 2H, NCH), 3.20 (br s, 2H, OH), 3.04 (dd, *J* = 4.0, 13.3, 2H, Bn CH₂), 2.79–2.65 (m, 4H, NCH₂), 2.39 (dd, *J* = 9.9, 13.3, 2H, Bn CH₂), 1.47 (s, 6H, CH₃). ¹³C NMR (CDCl₃, 100 MHz) δ: 139.12 and 139.10 (*s*-Bn), 128.99, 128.92, 128.53 and 128.47 (*o*-Bn, *m*-Bn), 127.29 and 126.17 (*p*-Bn), 109.36 [C(CH₃)₂], 80.51 (CHO), 63.12 (NCH), 60.80 (CH₂OH), 54.48 (N-Bn CH₂), 52.05 (NCH₂), 31.74 (Bn CH₂), 27.30 (CH₃). IR: ν = 3454, 3027, 2984, 2933, 2856, 1496, 1455, 1371, 1215, 1030, 735, 699 cm⁻¹. [α]_D²³ = -18.0 (c 1.05, MeOH). MS *m/z*: 608 (M⁺), 577, 517, 254, 91. Anal. calcd. for C₃₉H₄₈N₂O₄ (608.83): C, 76.94; H, 7.95; N, 4.60. Found: C, 76.87; H, 8.00; N, 4.57.

(2*S*,3*S*)-1,4-Bis{benzyl[(1*S*)-2-hydroxy-1-methylethyl]amino}-butane-2,3-diol, **11a**

HCl solution (6 N) (2 mL) was added to a solution of *N*-benzyl amine **10a** (103 mg, 0.23 mmol) in MeOH (3 mL), and the mixture was heated at 40°C for 22 h. Then 10 N NaOH solution was added in an ice-water bath until pH 8–9. After the addition of brine (5 mL), MeOH was evaporated, and the mixture was extracted with CH₂Cl₂ (4 × 10 mL). The organic phase was dried (Na₂SO₄), and solvent was evaporated. The residue was purified by column chromatography on silica gel (5% MeOH/NH₃ in CH₂Cl₂), affording tetraol **11a** as a white solid (yield 85 mg, 90%, mp 88–89°C). ¹H NMR (CDCl₃, 400 MHz) δ: 7.33–7.22 (m, 10H, Bn), 3.75 (d, *J* = 13.6, 2H, Bn CH₂), 3.59 (t, *J* = 6.3, 2H, CHOH), 3.52–3.38 (m, 6H, Bn CH₂, CH₂OH), 2.99–2.89 (m, 2H, CHCH₃), 2.70 (dd, *J* = 6.8, 13.4, 2H, NCH₂), 2.57 (dd, *J* = 6.3, 13.4, 2H, NCH₂), 0.93 (d, *J* = 6.7, 6H, CH₃). ¹³C NMR (CDCl₃, 100 MHz) δ: 139.44 (*s*-Bn), 128.77 (*o*-Bn), 128.50 (*m*-Bn), 127.19 (*p*-Bn), 69.26 (CHOH), 64.00 (CH₂OH), 57.18 (CHCH₃), 55.39 (Bn), 52.25 (NCH₂), 9.71 (CH₃). IR: ν = 3339, 3024, 2964, 2930, 2831, 1494, 1451, 1369, 1164, 1113, 1062, 726, 696 cm⁻¹. [α]_D²³ = +65.8 (c 1.71, MeOH). MS *m/z*: 417 (M⁺ + 1), 385, 238, 220, 178, 148, 130, 91. Anal. calcd. for C₂₄H₃₆N₂O₄ (416.57): C, 69.20; H, 8.71; N, 6.72. Found: C, 69.12; H, 8.72; N, 6.71.

(2*S*,3*S*)-1,4-Bis{benzyl[(1*S*)-1-benzyl-2-hydroxyethyl]amino}-butane-2,3-diol, **11b**

HCl solution (6 N) (10 mL) was added to a solution of *N*-benzyl amine **10b** (1.392 g, 2.29 mmol) in MeOH (15 mL) and the mixture was heated at 60°C for 19 h. Then 10 N NaOH solution was added in an ice-water bath until pH 8–9. After evaporation of MeOH, brine (30 mL) was added, and the mixture was extracted with CH₂Cl₂ (2 × 25 mL). The organic phase was dried (Na₂SO₄) and solvent was evaporated. The residue was purified by column chromatography on silica gel

(50% EtOAc in petroleum ether), affording tetraol **11b** as a white solid (yield 1.095 g, 84%, mp 44–49°C). ^1H NMR (CDCl_3 , 400 MHz) δ : 7.37–7.12 (m, 20H, Ar), 3.89 (d, $J=13.7$, 2H, N-Bn CH_2), 3.69 (m, 4H, N-Bn CH_2 , CHOH), 3.60 (m, 2H, CH_2OH), 3.55–3.48 (m, 2H, CH_2OH), 3.21 (br s, 4H, OH), 3.10–3.01 (m, 2H, NCH), 2.97 (dd, $J=5.2$, 13.4, 2H, Bn CH_2), 2.89 (dd, $J=6.7$, 13.3, 2H, NCH_2), 2.79 (dd, $J=6.9$, 13.3, 2H, NCH_2), 2.62 (dd, $J=9.2$, 13.4, 2H, Bn CH_2). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 139.38 and 139.26 (*s*-Bn), 129.02, 128.72, 128.53 and 128.50 (*o*-Bn, *m*-Bn), 127.25 and 126.15 (*p*-Bn), 69.00 (CHOH), 63.80 (NCH), 62.10 (CH_2OH), 55.98 (N-Bn CH_2), 52.88 (NCH_2), 32.33 (Bn CH_2). IR: $\nu=3368$, 3026, 2933, 2838, 1495, 1454, 1118, 1075, 1029, 738, 699 cm^{-1} . MS m/z : 567 (M^+-1), 537, 477, 314, 296, 284, 254, 224, 264, 91. Anal. calcd. for $\text{C}_{36}\text{H}_{44}\text{N}_2\text{O}_4$ (568.76): C, 76.02; H, 7.80; N, 4.93. Found: C, 75.73; H, 7.81; N, 4.88.

(2*S*,2'*S*,5*S*,5'*S*)-4,4'-Dibenzyl-5,5'-dimethyl-2,2'-bimorpholine, **12a**

Tetraol **11a** (85 mg, 0.20 mmol) in THF (20 mL) was added to NaH (41 mg, 1.02 mmol) at 0°C under an Ar atmosphere. The mixture was stirred at 0°C for 5 min and at rt for 1 h. The reaction mixture was cooled to 0°C, and 1-(*p*-toluenesulfonyl)imidazole (91 mg, 0.40 mmol) was added. After stirring for 15 min at 0°C, the reaction mixture was allowed to warm to rt and stirred for 42 h. The suspension was cooled to 0°C, and the reaction was quenched by dropwise addition of sat. NH_4Cl solution (5 mL). THF was evaporated, brine was added, and the mixture was extracted with EtOAc ($4 \times 20\text{ mL}$). The organic phase was dried (Na_2SO_4) and solvent was evaporated. The residue was purified by column chromatography on silica gel (2% MeOH/ NH_3 in CH_2Cl_2), affording dibenzyl bimorpholine **12a** as a yellow oil (yield 14 mg, 18%). ^1H NMR (CDCl_3 , 400 MHz) δ : 7.35–7.25 (m, 10H, Bn), 4.12 (d, $J=13.3$, 2H, Bn CH_2), 3.80 (dd, $J=3.3$, 11.2, 2H, OCH_2), 3.42–3.36 (m, 2H, OCH), 3.29–3.22 (m, 2H, OCH_2), 3.05 (d, $J=13.3$, 2H, Bn CH_2), 2.43 (m, 4H, NCH_2 , NCH), 2.12 (dd, $J=10.4$, 11.6, 2H, NCH_2), 1.05 (d, $J=6.2$, 6H, CH_3). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 138.56 (*s*-Bn), 129.00 (*o*-Bn), 128.16 (*m*-Bn), 126.83 (*p*-Bn), 73.16 (OCH_2), 58.04 (Bn), 55.34 (NCH), 53.15 (NCH_2), 15.32 (CH_3). IR: $\nu=3028$, 2963, 2892, 2841, 1494, 1453, 1377, 1106, 734, 699 cm^{-1} . $[\alpha]_{\text{D}}^{23}=+128.1$ (c 2.50, MeOH). MS m/z : 380 (M^+), 289, 217, 202, 188, 178, 91. Anal. calcd. for $\text{C}_{24}\text{H}_{32}\text{N}_2\text{O}_2$ (380.53): C, 75.75; H, 8.48; N, 7.36. Found: C, 75.57; H, 8.45; N, 7.33.

(2*S*,2'*S*,5*S*,5'*S*)-4,4',5,5'-Tetrabenzyl-2,2'-bimorpholine, **12b**

Tetraol **11b** (486 mg, 0.85 mmol) in THF (45 mL) was added to a suspension of NaH (171 mg, 4.27 mmol) in THF (40 mL) at 0°C under an Ar atmosphere. The mixture was stirred at 0°C for 5 min and at rt for 1 h. The reaction mixture was cooled to 0°C, and 1-(*p*-toluenesulfonyl)imidazole (380 mg, 1.71 mmol) was added. After stirring for 15 min at 0°C, the reaction mixture was allowed to warm to rt and stirred for 43 h. The suspension was cooled to 0°C, and the reaction was quenched by dropwise addition of sat. NH_4Cl solution (10 mL). THF was evaporated, brine was added, and the mixture was extracted with EtOAc ($2 \times 20\text{ mL}$). The organic phase was dried (Na_2SO_4), and solvent was evaporated. The residue

was purified by column chromatography on silica gel (30% EtOAc in petroleum ether), affording dibenzyl bimorpholine **12b** as a white solid (yield 287 mg, 63%, mp 47–55°C). ¹H NMR (CDCl₃, 800 MHz) δ: 7.31 (m, 8H, *m*, *o*-4,4'Bn), 7.26 (m, 2H, *p*-4,4'Bn), 7.23 (t, *J* = 7.5 Hz, 4H, *m*-5,5'Bn), 7.18 (t, *J* = 7.5 Hz, 2H, *p*-5,5'Bn), 7.14 (d, *J* = 7.5 Hz, 4H, *o*-5,5'Bn), 4.30 and 3.10 (2d, *J* = 13.3 Hz, 4H, 4,4'Bn CH₂), 3.67 (dd, *J* = 3.0 and 11.7 Hz, 2H, H-6,6'e), 3.33 (d, *J* = 10.5 Hz, 2H, H-2,2'a), 3.24 (dd, *J* = 10.1 and 11.7 Hz, 2H, H-6,6'a), 3.17 (dd, *J* = 4.2 and 14.2 Hz, 2H, 5,5'Bn), 2.64 (m, 2H, H-5,5'a), 2.48 (d, *J* = 12.0 Hz, 2H, H-3,3'e), 2.44 (dd, *J* = 8.8 and 14.2 Hz, 2H, 5,5'Bn), 2.20 (dd, *J* = 10.5 and 12.0 Hz, H-3,3'a). ¹³C NMR (CDCl₃, 201 MHz) δ: 138.79 (*s*-4,4'Bn), 138.59 (*s*-5,5'Bn), 129.23 (*o*-5,5'Bn), 129.11 (*o*-4,4'Bn), 128.53 (*m*-5,5'Bn), 128.47 (*m*-4,4'Bn), 127.14 (*p*-4,4'Bn), 126.44 (*p*-5,5'Bn), 76.35 (C-2,2'), 71.51 (C-6,6'), 61.29 (C-5,5'), 58.45 (4,4'Bn), 53.70 (C-3,3'), 36.51 (5,5'Bn). IR: ν = 3026, 2952, 2890, 2826, 1494, 1453, 1119, 740, 697 cm⁻¹. [α]_D²³ = +146.7 (c 1.05, EtOAc). MS *m/z*: 532 (M⁺), 441, 292, 266, 254, 91. Anal. calcd. for C₃₆H₄₀N₂O₂ (532.73): C, 81.17; H, 7.57; N, 5.26. Found: C, 80.95; H, 7.61; N, 5.23.

(2*S*,2'*S*,5*S*,5'*S*)-5,5'-Dibenzyl-2,2'-bimorpholine, **5**

To a solution of *N*-benzyl-bimorpholine **12b** (250 mg, 0.47 mmol) in THF (5 mL), 10% Pd/C (375 mg) and ammonium formate (148 mg, 2.35 mmol) were added under an Ar atmosphere. After heating the reaction mixture at 60°C for 6 h, the mixture was filtrated and washed with MeOH. MeOH was evaporated, and the crude mixture was purified by column chromatography (5% MeOH/NH₃ in CH₂Cl₂), affording bimorpholine **5** as a yellow oil (yield 149 mg, 90%). ¹H NMR (CDCl₃, 400 MHz) δ: 7.31–7.25 (m, 4H, *m*-Bn), 7.24–7.18 (m, 2H, *p*-Bn), 7.18–7.14 (m, 4H, *o*-Bn), 3.92 (dd, *J* = 3.0, 11.1, 2H, CH₂O), 3.44–3.38 (m, 2H, CHO), 3.31–3.25 (m, 2H, CH₂O), 3.02–2.94 (m, 2H, NHCH), 2.76–2.68 (m, 4H, NHCH₂), 2.64 (dd, *J* = 4.6, 13.4, 2H, Bn CH₂), 2.40 (dd, *J* = 9.2, 13.4, 2H, Bn CH₂), 1.71 (br s, 2H, NH). ¹³C NMR (CDCl₃, 100 MHz) δ: 137.67 (*s*-Bn), 129.09 (*o*-Bn), 128.58 (*m*-Bn), 126.53 (*p*-Bn), 76.68 (CHO), 72.66 (CH₂O), 55.55 (NHCH), 47.38 (NHCH₂), 38.56 (Bn CH₂). IR: ν = 3285, 3028, 2907, 2851, 1496, 1454, 1339, 1105, 746, 701 cm⁻¹. [α]_D²⁴ = –8.5 (c 2.24, MeOH). MS *m/z*: 353 (M⁺ + 1), 261, 204, 178, 128, 117, 91. Anal. calcd. for C₂₂H₂₈N₂O₂ (352.48): C, 74.97; H, 8.01; N, 7.95. Found: C, 74.71; H, 8.07; N, 7.89.

N,N-[[(4*S*,5*S*)-2,2-Dimethyl-1,3-dioxolane-4,5-diyl]di(methylene)]bis[*N*-[(1*S*)-2-hydroxy-1-methylethyl]-4-methylbenzenesulfonamide], **13a**

MgO (654 mg, 16.23 mmol) was added to a solution of amine **9a** (897 mg, 3.25 mmol) in THF (10 mL) and H₂O (2.5 mL) and the mixture was stirred at rt for 30 min. TsCl (1.238 g, 6.49 mmol) was added, and the mixture was stirred for 5 d. The mixture was filtered through celite, and the filtrate was washed with EtOAc. After the evaporation of solvents, the precipitate was dissolved in EtOAc (30 mL) and washed with H₂O (2 × 20 mL). The organic phase was dried (Na₂SO₄), and solvent was evaporated. The residue was purified by column chromatography on silica gel (50% EtOAc in petroleum ether), affording tosylamide **13a** as an

amorphous white solid (yield 980 g, 52%). ^1H NMR (MeOD, 400 MHz) δ : 7.82–7.78 (m, 4H, *o*-Ts), 7.35 (dd, $J=0.6, 8.6$, 4H, *m*-Ts), 3.97–3.88 (m, 4H, CHO, CHCH₃), 3.69 (d, $J=14.9$, 2H, NCH₂), 3.54 (dd, $J=7.1, 11.5$, 2H, CH₂OH), 3.45 (dd, $J=6.2, 11.5$, 2H, CH₂OH), 3.34–3.27 (m, 2H, NCH₂), 2.41 (s, 6H, *para*-CH₃), 1.35 (s, 6H, CCH₃), 1.17 (d, $J=6.9$, 6H, CHCH₃). ^{13}C NMR (MeOD, 100 MHz) δ : 144.81 (*p*-Ts), 139.13 (*s*-Ts), 130.70 (*m*-Ts), 128.48 (*o*-Ts), 110.97 [C(CH₃)₂], 81.55 (CHO), 64.38 (CH₂OH), 57.03 (CHCH₃), 47.40 (NCH₂), 27.33 [C(CH₃)₂], 21.45 (*p*-CH₃), 16.75 (CHCH₃). IR: $\nu=3522, 2984, 2936, 1599, 1375, 1329, 1244, 1156, 817\text{ cm}^{-1}$. $[\alpha]_{\text{D}}^{23}=-108.6$ (c 0.66, MeOH). MS m/z : 585 (M^++1), 569, 553, 509, 495, 284, 242, 212, 155, 91. Anal. calcd. for C₂₇H₄₀N₂O₈S₂ (584.76): C, 55.46; H, 6.89; N, 4.79; Found: C, 55.15; H, 6.92; N, 4.76.

N,N'*-[*(2S,3S)*-2,3-Dihydroxybutane-1,4-diyl]bis{*N*-[*(1S)*-2-hydroxy-1-methylethyl]-4-methylbenzenesulfonamide}, **14a*

To a solution of tosylamide **13a** (980 mg, 1.68 mmol) in MeOH (8 mL), 6 N HCl solution (5 mL) was added, and the mixture was heated at 55°C for 48 h. In an ice-water bath, 10 N NaOH solution was added until pH 8–9. After addition of brine (10 mL), MeOH was evaporated, and the mixture was extracted with CH₂Cl₂ (4 × 25 mL). The organic phase was dried (Na₂SO₄), and solvent was evaporated. The residue was purified by column chromatography on silica gel (3% MeOH in CH₂Cl₂), affording tetraol **14a** as a white solid (yield 838 mg, 92%, mp 56–61°C). ^1H NMR (MeOD, 400 MHz) δ : 7.77 (d, $J=8.0$, 4H, *o*-Ts), 7.39 (d, $J=8.0$, 4H, *m*-Ts), 4.00 (t, $J=6.3$, 2H, CHOH), 3.90 (dt, $J=6.9, 13.6$, 2H, CHCH₃), 3.58 (dd, $J=6.9, 11.4$, 2H, CH₂OH), 3.48 (dd, $J=6.1, 11.4$, 2H, CH₂OH), 3.34–3.19 (m, 4H, NCH₂), 2.42 (s, 6H, *p*-CH₃), 0.96 (d, $J=6.9$, 6H, CHCH₃). ^{13}C NMR (MeOD, 100 MHz) δ : 145.04 (*p*-Ts), 138.53 (*s*-Ts), 130.85 (*m*-Ts), 128.58 (*o*-Ts), 71.11 (CHOH), 65.55 (CH₂OH), 57.54 (NCH), 48.00 (NCH₂), 21.47 (*p*-CH₃), 14.75 (CHCH₃). IR: $\nu=3430, 2978, 2938, 1598, 1330, 1155, 817\text{ cm}^{-1}$. $[\alpha]_{\text{D}}^{23}=+37.5$ (c 0.66, MeOH). MS m/z : 513 ($\text{M}^+-\text{CH}_2\text{OH}$), 469, 242, 155, 91. Anal. calcd. for C₂₄H₃₆N₂O₈S₂ (544.69): C, 52.92; H, 6.66; N, 5.14. Found: C, 52.63; H, 6.69; N, 5.10.

(2S,2'S,5S,5'S)*-5,5'-Dimethyl-4,4'-bis[(4-methylphenyl)sulfonyl]-2,2'-bimorpholine, **15a*

Tetraol **14a** (1.304 g, 2.39 mmol) in THF (60 mL) was added to a suspension of NaH (479 mg, 11.97 mmol) in THF (180 mL) at 0°C under an Ar atmosphere. The mixture was stirred at 0°C for 5 min and at rt for 1 h. The reaction mixture was cooled to 0°C, and 1-(*p*-toluenesulfonyl)imidazole (1.064 g, 4.79 mmol) was added. After stirring for 15 min at 0°C, the reaction mixture was allowed to warm to rt and stirred for 90 h. The suspension was cooled to 0°C, and the reaction was quenched by dropwise addition of sat. NH₄Cl solution (15 mL). THF was evaporated, brine was added, and the mixture was extracted with EtOAc (3 × 30 mL). The organic phase was dried (Na₂SO₄), and solvent was evaporated. The residue was purified by column chromatography on silica gel (40% EtOAc in petroleum ether), affording ditozyl bimorpholine **15a** as a white solid (yield 862 mg, 71%, mp 62–68°C). ^1H NMR (CDCl₃, 400 MHz) δ : 7.68 (d, $J=8.0$, 4H, *o*-Ts), 7.35

(d, $J=8.0$, 4H, *m*-Ts), 3.83–3.73 (m, 4H, CHO, CH₂O), 3.64 (dd, $J=2.1$, 12.3, 2H, NCH₂), 3.30 (dd, $J=7.5$, 11.7, 2H, CH₂O), 3.09–3.00 (m, 2H, NCH), 2.85 (dd, $J=7.3$, 12.3, 2H, NCH₂), 2.45 (s, 6H, *p*-CH₃), 1.23 (d, $J=6.5$, 6H, CH₃). ¹³C NMR (CDCl₃, 100 MHz) δ : 143.82 (*p*-Ts), 134.47 (*s*-Ts), 129.84 (*m*-Ts), 127.48 (*o*-Ts), 72.99 (CHO), 70.64 (CH₂O), 51.53 (NCH), 45.89 (NCH₂), 21.53 (*para*-CH₃), 15.52 (CH₃). IR: $\nu=2977$, 2926, 2870, 1598, 1349, 1166, 1112, 817 cm⁻¹. $[\alpha]_D^{24}=+22.2$ (c 1.58, MeOH). MS m/z : 509 (M⁺+1), 353, 254, 240, 198, 155, 139, 100, 91.

(2*S*,2'*S*,5*S*,5'*S*)-5,5'-Dimethyl-2,2'-bimorpholine, **3**

Tosylamide **15a** (777 mg, 1.53 mmol) in THF (30 mL) was added to a suspension of LiAlH₄ (464 mg, 12.22 mmol) in THF (20 mL) at 0°C. After refluxing for 29 h, water (464 μ L), 15% NaOH solution (464 μ L), and water (1.4 mL) were added at 0°C. The mixture was filtered and washed with EtOAc. The filtrate was dried over Na₂SO₄. After filtration, solvents were evaporated, and the residue was purified by column chromatography on silica gel (7% MeOH/NH₃ in CH₂Cl₂), affording bimorpholine **3** as a white solid (yield 164 mg, 54%, mp 81–86°C). ¹H NMR (CDCl₃, 400 MHz) δ : 3.86 (dd, $J=3.1$, 11.1, 2H, CH₂O), 3.39–3.33 (m, 2H, CHO), 3.15–3.08 (m, 2H, CH₂O), 2.93–2.78 (m, 6H, CH₂NH, CHNH), 1.67 (br s, 2H, NH), 0.94 (d, $J=6.4$, 6H, CH₃). ¹³C NMR (CDCl₃, 100 MHz) δ : 76.92 (CHO), 74.09 (CH₂O), 49.85 (CHNH), 47.34 (CH₂NH), 17.51 (CH₃). IR: $\nu=3308$, 3272, 2970, 2898, 2860, 1444, 1377, 1105 cm⁻¹. $[\alpha]_D^{23}=+11.3$ (c 2.76, MeOH). MS m/z : 200 (M⁺), 169, 141, 128, 113, 102, 97, 70, 56. HRMS calcd. for C₁₀H₂₀N₂O₂ (M⁺+H) 201.15975; found 201.15991.

(4*S*,5*S*)-*N,N'*-Bis[(1*S*)-2-hydroxy-1-methylethyl]-2,2-dimethyl-1,3-dioxolane-4,5-dicarboxamide, **8c**

(*S*)-Alaninol **7a** (1.98 mL, 25.42 mmol) and sodium cyanide (62 mg, 1.27 mmol) were added to a solution of (*S,S*)-tartaric acid ester acetal **6c** (2.773 g, 12.71 mmol) in MeOH (42 mL). The reaction mixture was refluxed for 21 h. MeOH was evaporated, and the crude mixture was purified by column chromatography on silica gel (7% MeOH in CH₂Cl₂), affording amide **8c** as an amorphous white solid (yield 3.169 g, 82%). ¹H NMR (CDCl₃, 400 MHz) δ : 7.07 (d, $J=8.2$, 2H, NH), 4.58 (s, 2H, CHO), 4.13–4.01 (m, 2H, NHCH), 3.81 (t, $J=5.5$, 2H, OH), 3.66 (m, 2H, CH₂OH), 3.47 (m, 2H, CH₂OH), 1.46 (s, 6H, CCH₃), 1.17 (d, $J=6.8$, 6H, CHCH₃). ¹³C NMR (CDCl₃, 100 MHz) δ : 170.34 (C=O), 112.76 (C(CH₃)₂), 77.67 (CHO), 65.96 (CH₂OH), 47.65 (NHCH), 26.28 (CCH₃), 17.01 (CHCH₃). IR: $\nu=3408$, 3086, 2980, 2938, 2878, 1667, 1535, 1457, 1385, 1219, 1090, 1054 cm⁻¹. $[\alpha]_D^{24}=+16.5$ (c 3.68, MeOH). MS m/z : 305 (M⁺+1), 273, 255, 144, 114, 154. Anal. calcd. for C₁₃H₂₄N₂O₆ (304.35): C, 51.31; H, 7.95; N, 9.20. Found: C, 50.93; H, 7.97; N, 9.16.

(2*S*,2'*S*)-2,2'-[[(4*R*,5*R*)-2,2-Dimethyl-1,3-dioxolane-4,5-diyl]-bis(methyleneimino)]bis(3-phenylpropan-1-ol), **9c**

Amide **8c** (3.057 g, 10.04 mol) was added in THF (60 mL) to a suspension of LiAlH₄ (2.287 g, 60.27 mol) in THF (40 mL) at 0°C. After refluxing for 4 h, water

(2.3 mL), 15% NaOH solution (2.3 mL), and water (6.9 mL) were added at 0°C. The mixture was filtered and washed with EtOAc. The filtrate was dried over Na₂SO₄. After filtration, solvents were evaporated, and the residue was purified by column chromatography on silica gel (10–20% MeOH/NH₃ in CH₂Cl₂), affording amine **9c** as an amorphous yellow solid (yield 1.909 g, 69%). ¹H NMR (CDCl₃, 400 MHz) δ: 3.88–3.81 (m, 2H, CHO), 3.57 (dd, *J* = 3.9, 10.8, 2H, CH₂OH), 3.28 (dd, *J* = 7.0, 10.8, 2H, CH₂OH), 2.93 (ddd, *J* = 1.9, 4.6, 11.9, 2H, NHCH₂), 2.76 (pd, *J* = 3.9, 6.5, 2H, NHCH), 2.67 (dd, *J* = 4.1, 11.9, 2H, NHCH₂), 1.39 (s, 6H, CCH₃), 1.05 (d, *J* = 6.5, 6H, CHCH₃). ¹³C NMR (CDCl₃, 100 MHz) δ: 108.84 [C(CH₃)₂], 79.58 (CHO), 65.53 (CH₂OH), 54.85 (NHCH), 49.73 (NHCH₂), 27.14 (CCH₃), 17.01 (CHCH₃). IR: ν = 3307, 2933, 1459, 1380, 1250, 1057 cm⁻¹. [α]_D²³ = +56.8 (c 3.55, MeOH). MS *m/z*: 277 (M⁺ + 1), 261, 245, 187, 158, 144, 130, 100, 88. HRMS calcd. for C₁₂H₂₅N₂O₃ (M⁺ – CH₃OH) 245.1863; found 245.1860.

N,N'*-[[(4*R*,5*R*)-2,2-Dimethyl-1,3-dioxolane-4,5-diyl]di(methylene)]bis{*N*-[(1*S*)-2-hydroxy-1-methylethyl]-4-methylbenzenesulfonamide}, **13c*

MgO (1.094 g, 27.14 mmol) was added to a solution of amine **9c** (1.500 g, 5.43 mmol) in THF (18 mL) and water (4.5 mL) and the mixture was stirred at rt for 30 min. TsCl (2.069 g, 10.85 mmol) was added, and the mixture was stirred for 4 d. The mixture was filtered through celite, and the filtrate was washed with EtOAc. After the evaporation of solvents, the precipitate was dissolved in EtOAc (30 mL) and washed with water (3 × 30 mL). The organic phase was dried (Na₂SO₄), and solvent was evaporated. The residue was purified by column chromatography on silica gel (50% EtOAc in petroleum ether), affording tosylamide **13c** as an amorphous white solid (yield 2.005 g, 63%). ¹H NMR (CDCl₃, 400 MHz) δ: 7.78 (d, *J* = 8.1, 4H, *o*-Ts), 7.34 (d, *J* = 8.1, 4H, *m*-Ts), 4.32–4.24 (m, 2H, CHO), 4.02–3.91 (m, 2H, CHCH₃), 3.71 (d, *J* = 15.6, 2H NCH₂), 3.59–3.42 (m, 4H, CH₂OH), 3.38 (dd, *J* = 5.5, 9.2, 2H, OH), 3.08–2.97 (m, 2H, NCH₂), 2.44 (s, 6H, *para*-CH₃), 1.43 (s, 6H, CCH₃), 0.78 (d, *J* = 6.8, 6H, CHCH₃). ¹³C NMR (CDCl₃, 100 MHz) δ: 143.79 (*p*-Ts), 136.88 (*s*-Ts), 129.84 (*m*-Ts), 127.25 (*o*-Ts), 110.63 [C(CH₃)₂], 80.27 (CHO), 64.49 (CH₂OH), 55.49 (CHCH₃), 44.88 (NCH₂), 26.82 [C(CH₃)₂], 21.53 (*p*-CH₃), 12.84 (CHCH₃). IR: ν = 3510, 2981, 2938, 1598, 1384, 1325, 1246, 1156, 815 cm⁻¹. [α]_D²³ = +125.3 (c 2.37, MeOH). MS *m/z*: 553 (M⁺ – CH₂OH), 509, 495, 284, 242, 212, 155, 91. Anal. calcd. for C₂₇H₄₀N₂O₈S₂ (584.76): C, 55.46; H, 6.89; N, 4.79; Found: C, 55.47; H, 6.93; N, 4.74.

N,N'*-[(2*R*,3*R*)-2,3-Dihydroxybutane-1,4-diyl]bis{*N*-[(1*S*)-2-hydroxy-1-methylethyl]-4-methylbenzene-sulfonamide}, **14c*

To a solution of tosylamide **13c** (2.085 g, 3.57 mmol) in MeOH (15 mL), 6 N HCl solution (10 mL) was added, and the mixture was heated at 60°C for 22 h. In an ice-water bath, 10 N NaOH solution was added until pH 8–9. After addition of sat. NaCl solution (20 mL), MeOH was evaporated, and the mixture was extracted with CH₂Cl₂ (5 × 25 mL). The organic phase was dried (Na₂SO₄), and solvent was evaporated. The residue was purified by column chromatography on silica gel

(3% MeOH in CH₂Cl₂), affording tetraol **14c** as an amorphous white solid (yield 1.942 g, 100%). ¹H NMR (CDCl₃, 400 MHz) δ: 7.76 (d, *J* = 8.1, 4H, *o*-Ts), 7.33 (d, *J* = 8.1, 4H, *m*-Ts), 4.22–4.14 [m, 2H, CHOH], 4.03–3.93 (m, 2H, CHCH₃), 3.63–3.44 (m, 4H, CH₂OH), 3.40 (dd, *J* = 3.6, 15.3, 2H, NCH₂), 3.12 (dd, *J* = 9.1, 15.3, 2H, NCH₂), 2.43 (s, 6H, *p*-CH₃), 0.83 (d, *J* = 6.8, 6H, CHCH₃). ¹³C NMR (CDCl₃, 100 MHz) δ: 143.76 (*p*-Ts), 136.79 (*s*-Ts), 129.88 (*m*-Ts), 127.21 (*o*-Ts), 71.08 (CHOH), 64.41 (CH₂OH), 55.48 (NCH), 45.94 (NCH₂), 21.54 (*p*-CH₃), 13.11 (CHCH₃). IR: ν = 3421, 2978, 2930, 1598, 1333, 1155, 816 cm⁻¹. [α]_D²⁴ = +73.4 (c 1.97, MeOH). MS *m/z*: 513 (M⁺–CH₂OH), 495, 469, 242, 155, 91. Anal. calcd. for C₂₄H₃₆N₂O₈S₂ (544.69): C, 52.92; H, 6.66; N, 5.14. Found: C, 52.52; H, 6.63; N, 5.07.

(2*R*,2'*R*,5*S*,5'*S*)-5,5'-Dimethyl-4,4'-bis[(4-methylphenyl)sulfonyl]-2,2'-bimorpholine, 15c

Tetraol **14c** (1.916 g, 3.52 mmol) in THF (80 mL) was added to NaH (704 mg, 17.59 mmol) in THF (270 mL) at 0°C under Ar atmosphere. The mixture was stirred at 0°C for 5 min and at rt for 1 h. The reaction mixture was cooled to 0°C, and 1-(*p*-toluenesulfonyl)imidazole (1.564 g, 7.04 mmol) was added. After stirring for 15 min at 0°C, the reaction mixture was allowed to warm to rt and stirred for 22 h. The suspension was cooled to 0°C, and the reaction was quenched by dropwise addition of sat. NH₄Cl solution (50 mL). THF was evaporated, brine was added, and the mixture was extracted with EtOAc (3 × 30 mL). The organic phase was dried (Na₂SO₄). After filtration, solvents were evaporated, and the residue was purified by crystallization (in boiling MeOH). The mother liquid was purified by column chromatography on silica gel (50% EtOAc in petroleum ether), affording ditosyl bimorpholine **15c** as white crystals (yield 1.510 g, 84%, mp 174–177°C). ¹H NMR (CDCl₃, 400 MHz) δ: 7.69 (d, *J* = 8.0, 4H, *o*-Ts), 7.32 (d, *J* = 8.0, 4H, *m*-Ts), 4.01–3.93 (m, 2H, NCH), 3.61 (m, 4H, CH₂O), 3.50 (dd, *J* = 1.8, 12.7, 2H, NCH₂), 3.44–3.38 (m, 2H, CHO), 3.09 (dd, *J* = 10.6, 12.7, 2H, NCH₂), 2.44 (s, 6H, *p*-CH₃), 1.07 (d, *J* = 6.8, 6H, CH₃). ¹³C NMR (CDCl₃, 100 MHz) δ: 143.54 (*p*-Ts), 137.30 (*s*-Ts), 129.87 (*m*-Ts), 127.05 (*o*-Ts), 75.51 (CHO), 71.41 (CH₂O), 48.37 (NCH), 40.29 (NCH₂), 21.52 (*para*-CH₃), 13.65 (CH₃). IR: ν = 2982, 2932, 2874, 1600, 1341, 1157, 1123, 809 cm⁻¹. [α]_D²⁴ = +94.9 (c 2.37, CHCl₃). MS *m/z*: 353 (M⁺–Ts), 254, 198, 155, 100, 91. Anal. calcd. for C₂₄H₃₂N₂O₆S₂ (508.66): C, 56.67; H, 6.34; N, 5.51. Found: C, 56.67; H, 6.31; N, 5.49.

(2*R*,2'*R*,5*S*,5'*S*)-5,5'-Dimethyl-2,2'-bimorpholine, 4

Tosylamide **15c** (432 mg, 0.85 mmol) in THF (10 mL) was added to a suspension of LiAlH₄ (258 mg, 6.79 mmol) in THF (18 mL) at 0°C. After refluxing for 10 h, water (260 μ L), 15% NaOH solution (260 μ L), and water (780 μ L) were added at 0°C. The mixture was filtered and washed with EtOAc. The filtrate was dried over Na₂SO₄. After filtration, solvents were evaporated, and the residue was purified by column chromatography on silica gel (3–10% MeOH/NH₃ in CH₂Cl₂), affording bimorpholine **4** as a yellow oil, which solidifies in the freezer (yield 133 mg, 78%). ¹H NMR (CDCl₃, 400 MHz) δ: 3.73–3.61 (m, 6H, CHO, CH₂O), 3.02–2.90 (m,

4H, CHNH, CH₂NH), 2.80 (dd, $J=2.7, 12.6$, 2H, CH₂NH), 2.14 (br s, 2H, NH), 1.18 (d, $J=6.7$, 6H, CH₃). ¹³C NMR (CDCl₃, 100 MHz) δ : 74.46 (CHO), 70.47 (CH₂O), 47.99 (CHNH), 42.71 (CH₂NH), 16.88 (CH₃). IR: $\nu=3304, 3235, 2955, 2897, 2852, 1456, 1382, 1097\text{ cm}^{-1}$. $[\alpha]_{\text{D}}^{22}=-2.2$ (c 8.82, MeOH). MS m/z : 200, 141, 128, 114, 102, 97, 70.

ACKNOWLEDGMENTS

The authors thank the Estonian Science Foundation (Grant Nos. 6662 and 6778), the Ministry of Education and Research (Grant No. 0142725S06), and EU European Regional Development Fund (3.2.0101.08–0017) for financial support. The authors are grateful to Lauri Peil (Ph.D.), University of Tartu, Institute of Technology proteomics core facility, for HRMS analysis.

REFERENCES

1. Kizirian, J.-C. Chiral tertiary diamines in asymmetric synthesis. *Chem. Rev.* **2008**, *108*, 140–205.
2. Some examples of bioactive heterocycles: (a) Wang, X.; Bhatia, P. A.; Daanen, J. F.; Latsaw, S. P.; Rohde, J.; Kolasa, T.; Hakeem, A. A.; Matulenko, M. A.; Nakane, M.; Uchic, M. E.; Miller, L. N.; Chang, R.; Moreland, R. B.; Brioni, J. D.; Stewart, A. O. Synthesis and evaluation of 3-aryl piperidine analogs as potent and efficacious dopamine D₄ receptor agonists. *Bioorg. Med. Chem.* **2005**, *13*, 4667–4678; (b) Lima, E. C.; Domingos, J. L. O.; Dias, A. G.; Costa, P. R. R. First stereoselective synthesis and assignment of the absolute configuration of the nebracetam eutomer and derivatives. *Tetrahedron: Asymmetry* **2008**, *19*, 1161–1165; (c) Sudhakar, N.; Srinivasulu, G.; Rao, G. S.; Rao, B. V. The formal synthesis of isofebrifugine using stereoselective intramolecular Michael addition. *Tetrahedron: Asymmetry* **2008**, *19*, 2153–2158; (d) Lebrun, S.; Couture, A.; Deniau, E.; Grandclaudeon, P. Asymmetric synthesis of the optically active piperidine alkaloid (+)- β -conhydrine. *Tetrahedron: Asymmetry* **2008**, *19*, 1245–1249; (e) Shishido, Y.; Ito, F.; Morita, H.; Ikunaka, M. Stereoselective synthesis of a novel 2-aza-7-oxabicyclo[3.3.0]octane as neurokinin-1 receptor antagonist. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 6887–6890.
3. Bioactive compounds, containing morpholine moiety: (a) Wijtmans, R.; Vink, M. K. S.; Schoemaker, H. E.; van Delft, F. L.; Blaauw, R. H.; Rutjes, F. P. J. T. Biological relevance and synthesis of C-substituted morpholine derivatives. *Synthesis* **2004**, 641–662; (b) Fish, P. V.; Deur, C.; Gan, X.; Greene, K.; Hoople, D.; Mackenny, M.; Para, K. S.; Reeves, K.; Ryckmans, T.; Stiff, C.; Stobie, A.; Wakenhut, F.; Whitlock, G. A. Design and synthesis of morpholine derivatives: SAR for dual serotonin and noradrenaline reuptake inhibition. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 2562–2566; (c) Abramova, T. V.; Bakharev, P. A.; Vasilyeva, S. V.; Silnikov, V. N. Synthesis of morpholine nucleoside triphosphates. *Tetrahedron Lett.* **2004**, *45*, 4361–4364; (d) Harding, W. W.; Hodge, M.; Wang, Z.; Woolverton, W. L.; Parrish, D.; Deschamps, J. R.; Prinszano, T. E. Enantioselective synthesis of (2*R*,3*R*)- and (2*S*,3*S*)-2-[(3-chlorophenyl)-(2-methoxyphenoxy)methyl]morpholine. *Tetrahedron: Asymmetry* **2005**, *16*, 2249–2256; (e) Sladojevich, F.; Trabocchi, A.; Guarna, A. Stereoselective cyclopropanation of serine- and threonine-derived oxazines to access new morpholine-based scaffolds. *Org. Biomol. Chem.* **2008**, *6*, 3328–3336.

4. MacMillan, D. W. C. The advent and development of organocatalysis. *Nature* **2008**, *455*, 304–308.
5. Some recent reviews: (a) Mukherjee, S.; Yang, J. W.; Hoffmann, S.; List, B. Asymmetric enamine catalysis. *Chem. Rev.* **2007**, *107*, 5471–5569; (b) Erkkilä, A.; Majander, I.; Pihko, P. M. Iminium catalysis. *Chem. Rev.* **2007**, *107*, 5416–5470; (c) Sulzer-Mossé, S.; Alexakis, A. Chiral amines as organocatalysts for asymmetric conjugate addition to nitroolefins and vinyl sulfones via enamine activation. *Chem. Commun.* **2007**, 3123–3135.
6. (a) Kanger, T.; Laars, M.; Kriis, K.; Kailas, T.; Müürisepp, A.-M.; Pehk, T.; Lopp, M. Anchimeric assistance in the case of vicinal dimesylate: Formation of enantiomeric or meso-bimorpholine. *Synthesis* **2006**, *11*, 1853–1857; (b) Kanger, T.; Kriis, K.; Pehk, T.; Müürisepp, A.-M.; Lopp, M. Asymmetric synthesis of novel C_2 -symmetric bimorpholines. *Tetrahedron: Asymmetry* **2002**, *13*, 857–865.
7. (a) Laars, M.; Kriis, K.; Kailas, T.; Müürisepp, A.-M.; Pehk, T.; Kanger, T.; Lopp, M. Structural constraints for C_2 -symmetric heterocyclic organocatalysts in asymmetric aldol reactions. *Tetrahedron: Asymmetry* **2008**, *19*, 641–645; (b) Kanger, T.; Kriis, K.; Laars, M.; Kailas, T.; Müürisepp, A.-M.; Pehk, T.; Lopp, M. Bimorpholine-mediated enantioselective intramolecular and intermolecular aldol condensation. *J. Org. Chem.* **2007**, *72*, 5168–5173; (c) Kriis, K.; Laars, M.; Lippur, K.; Kanger, T. Bimorpholines as alternative organocatalysts in asymmetric aldol reactions. *Chimia* **2007**, *61*, 232–235; (d) Kriis, K.; Kanger, T.; Laars, M.; Kailas, T.; Müürisepp, A.-M.; Pehk, T.; Lopp, M. Enantioselective synthesis of Wieland–Miescher ketone through bimorpholine-catalyzed organocatalytic aldol condensation. *Synlett* **2006**, 1699–1702; (e) Mosse, S.; Laars, M.; Kriis, K.; Kanger, T.; Alexakis, A. 3,3'-bimorpholine derivatives as a new class of organocatalysts for asymmetric Michael addition. *Org. Lett.* **2006**, *8*, 2559–2562.
8. Lippur, K.; Kanger, T.; Kriis, K.; Kailas, T.; Müürisepp, A.-M.; Pehk, T.; Lopp, M. Synthesis of (2*S*,2'*S*)-bimorpholine *N,N'*-quaternary salts as chiral phase transfer catalysts. *Tetrahedron: Asymmetry* **2007**, *18*, 137–141.
9. (a) Kang, S. H.; Kim, M. Enantioselective mercuriocyclization of γ -hydroxy-cis-alkenes. *J. Am. Chem. Soc.* **2003**, *125*, 4684–4685; (b) Högberg, T.; Ström, P.; Ebner, M.; Rämby, S. Cyanide as an efficient and mild catalyst in the aminolysis of esters. *J. Org. Chem.* **1987**, *52*, 2033–2036.
10. Lanman, B. A.; Myers, A. G. Efficient, stereoselective synthesis of *trans*-2,5-disubstituted morpholines. *Org. Lett.* **2004**, *6*, 1045–1047.
11. Kang, H. H.; Rho, H. S.; Kim, D. H.; Oh, S.-G. Metal oxide in aqueous organic solution promoted chemoselective *N*-sulfonylation of hydrophilic amino alcohols. *Tetrahedron Lett.* **2003**, *44*, 7225–7227.
12. Choi, J. Y.; Borch, R. F. Highly efficient synthesis of enantiomerically enriched 2-hydroxymethylaziridines by enzymatic desymmetrization. *Org. Lett.* **2007**, *9*, 215–218.